United Historical Valuation

UTHR Stock  USD 370.49  7.64  2.02%   
Some fundamental drivers such as market cap or United Therapeutics enterprice value can be analyzed from historical perspective to project value of the company into the future. Some investors analyze United Therapeutics valuation indicators such as Market Cap of 12 B or Working Capital of 0.0 to time the market or to short-sell their positions based on the trend in valuation ratios. It is a perfect tool to project the direction of United Therapeutics's future value.
  
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in United Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in rate.
To learn how to invest in United Stock, please use our How to Invest in United Therapeutics guide.

About United Valuation Data Analysis

Valuation is the financial process of determining what United Therapeutics is worth. United Therapeutics valuation ratios put that insight into the context of a company's share price, where they serve as useful tools for evaluating and utilizing investment potential. United Therapeutics valuation ratios help investors to determine whether United Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in United with respect to the benefits of owning United Therapeutics security.

United Therapeutics Valuation Data Chart

As of 11/29/2024, Market Cap is likely to grow to about 12 B. Also, Enterprise Value is likely to grow to about 11.8 B

Working Capital

The difference between a company's current assets and current liabilities, indicating the liquidity and operational efficiency of the business.

Enterprise Value

Enterprise Value (or EV) is usually referred to as United Therapeutics theoretical takeover price. In the event of an acquisition, an acquirer would have to take on United Therapeutics debt, but would also pocket its cash. Enterprise Value is more accurate representation of United Therapeutics value than its market capitalization because it takes into account all of United Therapeutics existing debt. A measure of a company's total value, often used as a more comprehensive alternative to equity market capitalization that includes the market capitalization, plus total debt, minority interest and preferred shares, minus total cash and cash equivalents.

Pair Trading with United Therapeutics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if United Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in United Therapeutics will appreciate offsetting losses from the drop in the long position's value.

Moving together with United Stock

  0.64EWTX Edgewise TherapeuticsPairCorr
  0.65BHC Bausch Health CompaniesPairCorr

Moving against United Stock

  0.7HLN Haleon plcPairCorr
  0.67JNJ Johnson Johnson Fiscal Year End 28th of January 2025 PairCorr
  0.65MRK Merck Company Fiscal Year End 6th of February 2025 PairCorr
  0.65ZTS Zoetis IncPairCorr
  0.57LLY Eli Lilly Sell-off TrendPairCorr
The ability to find closely correlated positions to United Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace United Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back United Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling United Therapeutics to buy it.
The correlation of United Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as United Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if United Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for United Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Additional Tools for United Stock Analysis

When running United Therapeutics' price analysis, check to measure United Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy United Therapeutics is operating at the current time. Most of United Therapeutics' value examination focuses on studying past and present price action to predict the probability of United Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move United Therapeutics' price. Additionally, you may evaluate how the addition of United Therapeutics to your portfolios can decrease your overall portfolio volatility.